Caroline Baumal Biography and Net Worth

Caroline is a leading retina specialist who has been at the forefront of retina research and patient care for over 25 years. As chief medical officer, Caroline oversees medical affairs across Apellis’ full portfolio of retinal, rare disease, and neurological programs. Caroline serves as a professor of ophthalmology at New England Eye Center, Tufts Medical Center, specializing in diseases and surgery of the retina and vitreous. As a board-certified ophthalmologist, she has authored over 170 publications and has been recognized with numerous prestigious awards, including the Senior Achievement Award from the American Academy of Ophthalmology, the Crystal Apple Award from the American Society of Retina Specialists, and the Lifetime Achievement Award from the Vit-Buckle Society. She also has been involved with research and clinical trials investigating novel therapies for retinal diseases. Caroline studied biochemistry at McGill University and received an M.D. from the University of Toronto, where she also completed her ophthalmology residency.

What is Caroline Baumal's net worth?: The estimated net worth of Caroline Baumal is at least $1.64 million as of January 4th, 2024. Dr. Baumal owns 32,931 shares of Apellis Pharmaceuticals stock worth more than $1,641,940 as of April 27th. This net worth approximation does not reflect any other investments that Dr. Baumal may own. Learn More about Caroline Baumal's net worth.
How do I contact Caroline Baumal?: The corporate mailing address for Dr. Baumal and other Apellis Pharmaceuticals executives is 100 FIFTH AVENUE, WALTHAM MA, 02451. Apellis Pharmaceuticals can also be reached via phone at (617) 977-5700 and via email at [email protected]. Learn More on Caroline Baumal's contact information.
Has Caroline Baumal been buying or selling shares of Apellis Pharmaceuticals?: Caroline Baumal has not been actively trading shares of Apellis Pharmaceuticals during the past quarter. Most recently, Caroline Baumal sold 2,751 shares of the business's stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $60.05, for a transaction totalling $165,197.55. Following the completion of the sale, the insider now directly owns 32,931 shares of the company's stock, valued at $1,977,506.55. Learn More on Caroline Baumal's trading history.
Who are Apellis Pharmaceuticals' active insiders?: Apellis Pharmaceuticals' insider roster includes Caroline Baumal (Insider), Victoria Brown (Insider), James Chopas (CAO), Mark DeLong (SVP), Pascal Deschatelets (Insider), A. Dunlop (Director), Jeffrey Eisele (Insider), Cedric Francois (CEO), Federico Grossi (Insider), Karen Lewis (Insider), Alec Machiels (Director), Nur Nicholson (Insider), Nicole Perry (VP), Lukas Scheibler (Insider), Timothy Sullivan (CFO), Adam Townsend (Insider), and David Watson (General Counsel). Learn More on Apellis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Apellis Pharmaceuticals?: During the last twelve months, insiders at the sold shares 55 times. They sold a total of 832,985 shares worth more than $51,199,751.25. The most recent insider tranaction occured on April, 8th when insider Pascal Deschatelets sold 69,107 shares worth more than $3,743,526.19. Insiders at Apellis Pharmaceuticals own 7.5% of the company. Learn More about insider trades at Apellis Pharmaceuticals.
Information on this page was last updated on 4/8/2024.

Caroline Baumal Insider Trading History at Apellis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/4/2024	Sell	2,751	$60.05	$165,197.55	32,931

Caroline Baumal Buying and Selling Activity at Apellis Pharmaceuticals

Apellis Pharmaceuticals Company Overview

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Today's Range

Now: $49.86

$48.85

$50.98

50 Day Range

MA: $57.84

$47.51

$71.73

2 Week Range

Now: $49.86

$19.83

$94.75

Volume

1,215,021 shs

Average Volume

1,146,601 shs

Market Capitalization

$6.01 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88

Better than Bitcoin? The Biotech Stock with 46,751% Potential

From Behind the Markets | Ad

4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.

Get the name of the stock here >>>